- Home
- WIMI vs BOLD Comparison
WIMI vs BOLD Comparison
Compare WIMI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WIMI | BOLD |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 28.4M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | WIMI | BOLD |
|---|---|---|
| Price | $2.58 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 108.2K | ★ 125.9K |
| Earning Date | 04-24-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $61,329,146.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $1.00 |
| 52 Week High | $9.66 | $2.54 |
Technical Indicators
Market Signals| Indicator | WIMI | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 46.13 |
| Support Level | $2.55 | $1.19 |
| Resistance Level | $2.85 | $1.31 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 20.59 | 12.50 |
Price Performance
Historical ComparisonAbout WIMI WiMi Hologram Cloud Inc.
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.